SVB Securities Sticks to Its Buy Rating for Vir Biotechnology (VIR)

In a report released on December 19, Roanna Ruiz from SVB Securities reiterated a Buy rating on Vir Biotechnology (VIRResearch Report), with a price target of $45.00. The company’s shares closed yesterday at $25.52.

Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, scPharmaceuticals, and Vir Biotechnology. According to TipRanks, Ruiz has an average return of -43.2% and a 13.46% success rate on recommended stocks.

Currently, the analyst consensus on Vir Biotechnology is a Moderate Buy with an average price target of $55.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $47.23 and a one-year low of $18.05. Currently, Vir Biotechnology has an average volume of 919.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vir Biotechnology, Inc. engages in the provision of technologies to treat and prevent infectious diseases. Its technology platforms include antibody, T cell, innate immunity, and siRNA. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in 2016 and is headquartered in San Francisco, CA.

Read More on VIR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More